Popular Diabetes Drug May Raise Risk of Vision Loss
A new study from the University of Toronto has raised concerns about a well-known diabetes and weight-loss drug.
Researchers found that older adults with diabetes who took semaglutide—a medicine sold under the brand names Ozempic and Wegovy—had more than twice the risk of developing a serious eye condition called neovascular age-related macular degeneration (nAMD).
nAMD is a dangerous form of age-related macular degeneration, the top cause of vision loss among older adults in Western countries.
- It is less common than the dry form but can cause quick and lasting damage to central vision.
- This happens when abnormal blood vessels grow in the retina and leak fluid or blood, harming the macula—the part of the eye that allows us to see clearly and directly in front of us.
Semaglutide is part of a group of medications called GLP-1 receptor agonists.
No direct quotes available in the text.
Author's summary: Diabetes drug semaglutide may increase vision loss risk.
More News
- Leylah Fernandez lifts fifth career title with Japan Open win
- YOUR SUNDAY READING LIST: Emergency Nudity, ICE on Parade, and Portland's Hero Frogs
- Como 2-0 Juventus: Nico Paz puts toothless Old Lady to the torch
- Nico Paz decisive: Juve loses in Como before Bernabéu visit
- ‘SNL’ recap: Best moments from Sabrina Carpenter hosting ‘Saturday Night Live’
- Keanu Reeves Just Responded to Those Alexandra Grant Marriage Rumors